Immunotherapy uses the body's immune system to recognize and destroy cancer cells. One way to do this is through immune ...

To understand the complement system’s involvement in ACS, Stowell and his team assessed the blood of 27 sickle-cell-disease patients experiencing ACS for signs of complement activation.

Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under review by FDA for the treatment of hematopoietic ...

The hazard of the progression of intermediate age-related macular degeneration (iAMD) was higher in those whose complement pathways were not regulated.

Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under priority review by FDA for the treatment of ...

Components of the lectin pathway of the complement system may affect the VTE risk through downstream complement activation and interactions with the coagulation system. Pattern recognition molecules ...

Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under review by FDA for the treatment of hematopoietic ...

Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under review by FDA for the treatment of hematopoietic ...

In the lectin pathway, carbohydrate epitopes on microbes are recognized. The third is the alternative pathway, which is an amplifier of those two pathways.

Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic ...

Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic ...